Innate Pharma SA (IPHA) income statement
IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30
$1.33−0.07 (-5.34%)
Close on Nov 17, 2026Market cap $124.65MP/E –Yield –
Innate Pharma SA income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -599.8%
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 0.60
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 19.7%
Valuation
- P/E ratio
- –
- Price to sales
- 12.54
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?